Chicago Ridge, ILNCT06695845Now EnrollingIRB Ready

Solid Tumors Clinical Trial in Chicago Ridge, IL

Access cutting-edge solid tumors treatment through this phase 2 clinical trial at a research site in Chicago Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Jazz Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Chicago Ridge location

Preparing your pre-screening questions…

Expert Care in Chicago Ridge

Access solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumors treatment provided free

Apply for This Chicago Ridge Location

Check if you qualify for this solid tumors clinical trial in Chicago Ridge, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago Ridge

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago Ridge site if eligible
  4. 4Begin participation

About This Solid Tumors Study in Chicago Ridge

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Sponsor: Jazz Pharmaceuticals

Who Can Participate

Inclusion Criteria

Is at least 18 years of age inclusive at the time of signing the informed consent
Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with HER2-targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.
HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory.
All participants must have adequate tumor sample for submission to allow central HER2 testing.
Presence of at least 1 measurable lesion as assessed by Independent Central Review (ICR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Has a life expectancy of at least 3 months, in the opinion of the investigator.
Participants with history of treated and stable CNS metastases are eligible, provided the following criteria are met:
Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.
Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \< Grade 1 (CTCAE Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment \> 7 days prior to Cycle 1 Day 1.
Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.
Adequate organ functions.
Females of childbearing potential must have a negative pregnancy test result.
Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.

Exclusion Criteria

Has known or suspected leptomeningeal disease and/or untreated brain metastasis.
Has uncontrolled or significant cardiovascular disease
Has ongoing toxicity related to prior cancer therapy
Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.
Has known Human Immunodeficiency Virus (HIV) infection.
Has active hepatitis B or C infection.
Has an active SARS-CoV-2 infection.
Has a history of life-threatening hypersensitivity to monoclonal antibody (mAbs) or to recombinant proteins or excipients in the drug formulation of zanidatamab.
Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site.
Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.
Prior treatment with HER2-targeted therapy (Cohort 1 only).
Has a history of trauma or major surgery
Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
Received zanidatamab at any time prior to the current study.
Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations.
Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.
Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.
Prior or concurrent invasive malignancy other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago Ridge?

Yes, this clinical trial (NCT06695845) has an active research site in Chicago Ridge, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors Treatment Options in Chicago Ridge, IL

If you're searching for solid tumors treatment options in Chicago Ridge, IL, this clinical trial (NCT06695845) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago Ridge research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Chicago Ridge, IL

See all advanced solid tumors clinical trials recruiting in Chicago Ridge — not just this study.

Browse Advanced Solid Tumors Trials in Chicago Ridge →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Chicago Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago Ridge, IL